Krebs Biochemicals & IND

NSE: KREBSBIO · Pharmaceuticals · sector

₹62.22NSE close 2026-10-26

Key numbers

Market cap₹134 cr

Price₹62.22

52w high / low₹77 / ₹38

P/E–Sector median 27.9x

P/B–Sector median 2.9x

Book value₹-75.5

Dividend yield–Sector median 0.48%

ROE–Sector median 11.7%

ROCE-10.9%Sector median 12.3%

OPM-10.1%Sector median 14.0%

Debt / equity–Sector median 0.16x

EV/EBITDA–Sector median 18.6x

Interest cover-0.9x

Current ratio0.09x

Sales growth 3y-23.1%Sector median +9.6%

Profit growth 3y–Sector median +13.3%

PEG–

Last 12 months to Jun 2026, Standalone. "Sector median" = middle value of 185 companies in Pharmaceuticals (P/E median leaves out loss-making companies). Tap ? for what a number means.

Things to know

Cash ₹0 cr vs borrowings ₹225 cr (FY26): borrowings are higher by ₹225 cr.
Borrowings rose in each of the last 3 years (₹183 cr → ₹225 cr).
Operating profit covered interest -0.9x in the last 12 months.
No promoter shares are pledged.
Operating cash flow was below net profit in 1 of the last 5 years (FY23).
Net loss in 8 of the last 8 quarters.
Revenue was higher than a year earlier in 2 of the last 4 quarters.
Debtor days went from 14 (FY24) to 0 (FY26).
No dividend in the last 5 financial years.
Price ₹62.22 on 2026-10-26: -19.0% from the 52-week high, +62.3% from the 52-week low.

Plain facts from the filings, built by the same fixed rules for every company. A line appears only when the data for it is available. Not a view on the stock.

Charts

Weekly close · high ₹112.93 · low ₹44.44

Quarterly results

₹ cr	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Revenue	13	11	6	5	4	7	7	7
EBITDA	-3	-5	-5	-2	-3	0	-1	1
OPM %	-21.1%	-41.2%	-88.7%	-38.1%	-66.9%	4.1%	-12.8%	11.9%
Other income	0	0	0	0	0	0	2	0
Net profit	-6	-8	-8	-5	-6	-3	-2	-2
EPS (₹)	-2.67	-3.59	-3.83	-2.47	-2.85	-1.45	-1.09	-1.15
Revenue YoY					-67.6%	-36.6%	+11.6%	+27.4%
Profit YoY					–	–	–	–

Standalone figures where filed. Latest quarter Jun 2026.

Profit & loss (yearly)

₹ cr	FY22	FY23	FY24	FY25	FY26	TTM
Revenue	53	52	50	43	24	25
EBITDA	-41	-16	-9	-15	-5	-3
Net profit	-45	-25	-20	-27	-17	-14
EPS (₹)	-20.81	-11.30	-9.16	-12.49	-7.85	-6.54
Revenue growth		-1.5%	-3.3%	-14.1%	-45.2%	-29.7%
Profit growth		–	–	–	–	–
Dividend / share (₹)	–	–	–	–	–

Compounded growth	3 years	5 years	Last 12 months
Sales	-23.1%	-15.1%	-29.7%
Net profit	–	–	–
EPS	–	–	–
Share price	–	-15.4% (2y)	-18.4%

Balance sheet

₹ cr	FY22	FY23	FY24	FY25	FY26
Shareholders' equity	–	-99	-119	-146	-163
Borrowings	–	183	193	212	225
Cash & equivalents	–	0	0	0	0
Total assets	–	175	178	169	163
Fixed assets	–	146	149	145	141
Capital work in progress	–	2	0	1	2
Investments	–	0	0	0	0
Receivables	–	1	2	0	0
Inventory	–	12	10	6	6
Payables	–	15	19	18	14

Year-end figures from the March annual filing.

Cash flow

₹ cr	FY22	FY23	FY24	FY25	FY26
Cash from operations	-17	-26	2	-8	-2
Cash from investing	-23	-11	-8	-5	-4
Cash from financing	40	37	6	13	6
Capex	27	11	8	5	4
Free cash flow	-44	-37	-6	-13	-6

Free cash flow = cash from operations − capex.

Ratios by year

₹ cr	FY22	FY23	FY24	FY25	FY26
ROE %	–	24.8%	16.5%	18.4%	10.4%
ROCE %	–	-25.9%	-20.3%	-31.8%	-15.9%
Debtor days	–	4	14	0	0
Inventory days	–	170	543	396	5,330
Payable days	–	217	1,051	1,193	12,857
Cash conversion cycle (days)	–	-43	-494	-797	-7,527
Working capital days	–	-231	-321	-786	-1,591

Shareholding

Holder	% (2026-09-30)
Promoters	72.74%
FIIs	0.50%
Public (non-institutions)	26.76%

Quarter	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026	Sep 2026
Promoters %	72.74%	72.74%	72.74%	72.74%	72.74%	72.74%	72.74%	72.74%

Promoter group	%
Ipca Laboratories Limited	49.65%
Hemalatha Ravi	12.48%
Avinash Ravi	9.93%
Ajay Ravi	0.52%
DR R T Ravi	0.11%
Aditya Ravi	0.05%

Public holders above 1%	%
SUN Pharmaceutical Industries Ltd	4.81%
Guttikonda Rajasekhar	1.86%
Guttikonda Vara Lakshmi	1.70%

8,533 shareholders. Pledged: 0.00% of promoter shares.

Peers in Pharmaceuticals

Company	Market cap	P/E	P/B	ROE	ROCE	OPM	Sales 3y	Div yield
SUNPHARMA	₹4,17,478 cr	34.5x	5.0x	15.5%	18.7%	28.6%	+10.0%	0.94%
DIVISLAB	₹2,39,825 cr	82.1x	14.3x	18.4%	23.0%	34.7%	+10.8%	0.34%
TORNTPHARM	₹1,53,999 cr	72.7x	18.4x	27.3%	15.1%	32.3%	+13.3%	0.84%
ZYDUSLIFE	₹1,15,808 cr	25.9x	4.3x	17.7%	16.8%	27.2%	+16.4%	0.95%
LAURUSLABS	₹1,11,232 cr	101.6x	21.0x	22.4%	20.8%	28.0%	+4.1%	0.08%
CIPLA	₹1,09,464 cr	32.5x	3.2x	10.3%	13.2%	17.7%	+7.4%	1.18%
DRREDDY	₹1,09,460 cr	33.9x	2.9x	9.0%	10.1%	15.5%	+11.0%	0.61%
MANKIND	₹95,486 cr	46.7x	5.9x	13.4%	13.8%	25.1%	+17.7%	0.04%
AUROPHARMA	₹91,489 cr	24.9x	2.4x	10.5%	12.8%	20.0%	+10.6%	0.26%
KREBSBIO	₹134 cr	–	–	–	-10.9%	-10.1%	-23.1%	–

All 185 companies in Pharmaceuticals →

Dividends & corporate actions

Ex-date	Action	Detail
2023-09-20	Other	Annual General Meeting
2021-09-15	Other	Annual General Meeting
2020-09-16	Other	Annual General Meeting
2019-09-13	Other	Annual General Meeting
2019-01-31	Rights	Rights 21:100 @ Premium Rs 76 Per Share
2018-08-30	Other	Annual General Meeting
2017-09-14	Other	Annual General Meeting
2016-09-20	Other	Annual General Meeting
2015-09-23	Other	Annual General Meeting
2013-12-16	Other	Annual General Meeting
2012-09-20	Other	Annual General Meeting
2011-09-22	Other	Annual General Meeting
2010-08-16	Other	Annual General Meeting
2009-09-03	Other	Annual General Meeting
2008-09-15	Other	Annual General Meeting
2007-09-19	Other	Agm Bc End Date Revised
2005-09-14	Dividend	Agm/Dividend-30% Purpose Revised
2004-09-21	Dividend	Dividend-80%

Documents

Links go to the original files on the exchange website.

About the company


Sector	Healthcare
Industry	Pharmaceuticals
Sub-industry	Pharmaceuticals
Symbol	KREBSBIO
BSE code	524518
ISIN	INE268B01013
Face value	₹10.0
Incorporated	–
Website	–
Plants (India / abroad)	–

Data built 2026-10-23 from NSE company filings (XBRL: Integrated Filing - Financials + financial results), NSE shareholding & pledge data; price = NSE close 2026-10-26.